Immunemonitoring of patients scheduled for liver transplantation and resection

Immunemonitoring of patients scheduled for liver transplantation and resection - LiMun Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00013567

Enrollment

Registered

2019-08-08

Start date

2016-06-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C22.0

Interventions

Group 1: Operative Treatment of HCC (Resection and Transplantation) Group 2: Healthy controls

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Informed Consent, at least 18y of age, no previous Treatment, scheduled for resection or transplantation

Exclusion criteria

Exclusion criteria: No consent, underaged, pregnant, prior treatment 6 weeks prioir inclusion in study, other malignancies, infection, prior treatment in the liver 6 weeks prioir inclusion in study (e.g. TACE, RFA etc.)

Design outcomes

Primary

Measure	Time frame
Aim of this study is to identify immunological markers for risk stratification of HCC patients	—

Secondary

Measure	Time frame
With sttistical modelling we want to calculate the sensistivity and specificity for the newly discovered markers	—

Countries

Germany

Contacts

Public ContactMarkus Schoenberg

Klinikum der LMU MünchenKlinik für Allgemeine, Viszerale und Transplantationschirurgie

markus.schoenberg@med.uni-muenchen.de08944001683524

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 14, 2026